Dr. Gregory Daniel Lendzion, DO

Dr. Lendzion practices at Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group.

Dr. Lendzion's NPI, 1104069491, was assigned on April 16, 2009. Dr. Lendzion holds Michigan license 5101018264.

Dr. Lendzion's primary practice is Bronson Methodist Hospital, at 601 John Street, Kalamazoo, MI 49007 in Kalamazoo County. The practice phone is (269) 341-6000.

Dr. Lendzion's primary practice is Bronson Methodist Hospital in Kalamazoo, Michigan, part of Bronson Healthcare Group. Dr. Lendzion is also affiliated with Bronson Battle Creek Hospital. The medical group on file is Bronson Medical Group. Dmand AI also links Dr. Lendzion to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lendzion practices, 5 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Lendzion's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Lendzion is board certified in emergency medicine by the American Board of Emergency Medicine. Dr. Lendzion is licensed in Michigan.

CMS data shows 165 Medicare services from Dr. Lendzion across 3 procedure codes in 2024, for 139 Medicare patients. Medicare paid $15,267 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 139 Medicare patients who saw Dr. Lendzion in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lendzion's median patient age at 51, with 60% women.

In 2024, Dr. Lendzion wrote 112 Medicare Part D claims for 89 patients. 89% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $160 in total drug cost. In 2023, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Lendzion for performance year 2024, reported as part of a group. Dr. Lendzion accepts Medicare assignment, so Medicare's approved amount is taken as full payment.